On Asking the Right Questions, with Patrick Howson

“The only reason I chose neuroscience,” says Patrick Howson, Atuka’s Chief Innovation Officer, “is because of where I randomly placed a pin on the prospectus for my university’s science department.” Patrick knew at an early age growing up in Leicester that he liked science and was good at it. For most of his school years he wanted to be a physician but work experience shadowing a doctor made him realize this wasn’t the path for him. While high school students in the UK are only required to complete three A-levels, Patrick elected to do a fourth, so he could study  maths, physics, chemistry, and biology.  

“After deciding against medicine, I didn’t really know what I wanted to do science-wise,” he says, “I could’ve done all of them.” That’s when Patrick used the pin, hammered into the side of the prospectus, to narrow his options. “The indent the pin left was on neuroscience.”    

Not that the decision has constrained him much since, Patrick insisting that his choice of degree has not defined the course of his life’s work. He’s certainly had the most varied career among Atuka’s scientific leadership, with time spent in drug discovery and development at a UK-based virtual biotech, and a postdoc degree at a chemistry lab in Bristol under Jeff Watkins, which is where Patrick became more interested in the process of taking an interesting finding through to a clinical trial and evaluating its potential as a therapeutic.   

“I guess I’ve always been more interested in the practical uses of science than cutting edge, theoretical science,” says Patrick. “And my experience has given me a broad overview of the process of developing therapeutics, as well as ancillary things like patent generation, regulatory requirements, and how to build a commercializable position.” 

____

How does your expertise differ from the other scientific leadership at Atuka? 

In terms of experience, there’s a definite difference between myself and the other lead scientists—they’re all Parkinson’s experts. Their PhDs were in Parkinson’s, and they stayed in Parkinson’s research throughout their careers, and in preclinical research. For the past 20 years I have worked mainly in PD, so it’s not like I’m a novice in this field. It’s just that the others have 30-40 years’ experience.  

But you have a diversity of experience and breadth of knowledge that perhaps they don’t? How does that serve you as Atuka’s Chief Innovation Officer? 

What I do have is a breadth of knowledge, which helps me ask more of those “what if” questions, because I’m not encumbered by knowledge. It’s a beautiful relief when you don’t know the field so well. It allows you to think of ideas that people who know the field better might instantly dismiss out of hand, because there’s always 10 or 15 reasons why it’s a stupid idea, but the broad perspective sometimes allows you to see things that they aren’t able to. When you’ve got breadth, you may not know all the answers, but often you know some of the main questions to ask. 

You’ve said that it almost doesn’t matter that you chose neuroscience. What do you mean by that? 

 I guess science for me is mainly problem-solving. It doesn’t really matter whether it’s a problem of, how do you build preclinical models of PD that capture a facet of the disease, how do you make a chemical with the right purity and right profile to go into humans, or how do you interpret results from a toxicology study, and what do they mean? Much of that’s not neuroscience, it’s just problem-solving. Obviously there have been neuroscience problems along the way as well, but for me science was essentially my way of understanding the world. It’s the lens I see the world through. 

I’ve never been interested in just one area of science. For a while after doing my PhD, I considered moving into mathematical modelling of non-linear biological systems. Later, I did a post-doc in a chemistry-driven lab. When I was at a drug development company, I worked on anti-obesity, anti-inflammatories, canine osteoarthritis, eczema, dog eczema, Parkinson’s, Alzheimer’s, ALS. A very broad range of conditions, and they’re all interesting to learn about.  

I’m very happy not being the expert in the room on any disease. But, again, you can always bring more out of the actual experts by asking the right questions.  

Perhaps because you brought up math, I’m reminded how OpenAI recently released an AI-generated proof that solved some longstanding mathematics problem. So we saw some news stories with mathematicians getting philosophical about the meaning or value of their work as a result. How does that sort of existential worry carry over to scientists? Or should we care if the goal is to cure diseases and save lives? 

If I put myself in that mathematician’s position, if AI came along and cured PD, I wouldn’t be disappointed, I would be absolutely over the moon. And I think the response from mathematicians has been a complex mix of excitement, shock, and anxiety. I don’t know if I’ve seen any mathematician actually saying that AI solving this proof is a bad thing. One of the major strengths of AI is taking the composite knowledge from thousands and thousands of mathematicians—the information was already out there—and synthesizing it in a way which has addressed long-standing problems. If I was a mathematician who had worked 40 years on a problem and it was solved, I’d prefer that than having worked 40 years on it and then dying before seeing it solved.  

Newsletter

Atuka의 최신 과학 연구 소식을 받아보세요

파킨슨병 연구의 최신 동향을 담은 분기별 뉴스레터를 받아보시려면 구독하세요.

메일링 리스트 등록

Talk to our experts

치료제 개발 프로그램을 성공으로 이끄세요